According to a new study, patients being treated for sarcoma, a rare type of cancer, are more willing to take “telemedicine” (telemedicine with a doctor).
Researchers at the University of Strathclyde and the Scottish Sarcoma Network set out to understand sarcoma patientAttitudes and impacts on telemedicine from an anonymous online survey in the summer of 2020.
Every year in Scotland, about 350 people are diagnosed with sarcoma, a rare group of cancers that affect connective tissue, and are treated at one of five specialized medical centers nationwide.
The results of a study published in the journal JCO Global Oncology showed that patients were highly satisfied with telemedicine and were comparable to traditional face-to-face appointments.
The majority of patients (57%) indicated that they preferred telemedicine appointments for the majority. Factors commonly cited in this decision include reduced hospital travel times, reduced hospital travel costs, reduced hospital waiting times, and their convenience.
A survey comment from a 58-year-old male patient said: If necessary, have them meet in person. “
Patients who primarily prefer face-to-face appointments said it was more reassuring, but patients who are currently receiving treatment or who have completed treatment in the last 6 months prefer primarily or wholly face-to-face appointments. It was likely to show that.
Age, gender, and education level have not been shown to affect patient preferences. More than half of the patients who have been booked for telemedicine have met someone who has seen them before.
However, he was keen to receive bad news face-to-face rather than remotely.
For clinicians and healthcare providers, the workload of telemedicine is about the same as face-to-face consultation, and two-thirds said telemedicine needs to be integrated into regular practice.
Dr. Ioana Nixon, a head and neck and sarcoma oncologist at the Scottish Cancer Center, a clinical leader in the Scottish Sarcoma Network, a visiting professor at the University of Strathclyde, and a senior author of the paper, said: Stated. Changes had to be made to safely provide cancer services. Telemedicine is one of them, and as a clinician, it is important to understand how patients are experiencing this change.
“Sarcoma is a very rare and diverse cancer, and our research aims to understand how telemedicine can be best used in this rare cancer. cancer.. Without a doubt, there is no one-size-fits-all approach. We hope that our research will help put patient needs at the center of the service and help shape and reform the service around what is important to the patient. “
Holly McCabe, a student in the School of Business Sciences who analyzed her PhD survey, said: “Our study has shown that telemedicine in the treatment of sarcoma is advantageous from both the clinician’s and patient’s perspectives.
“Using telemedicine for patients with rare cancers such as sarcomas is an innovation to provide care, especially given the time and financial pressure on patients who often live far from specialized centers. Approach.
Future work will assess how a model of patient-specialist consultation in the treatment of sarcoma is adopted, from diagnosis to follow-up. They “have an important opportunity to explore patient and professional awareness and preferences for these approaches and provide important information to inform the long-term remodeling of sarcoma clinics. Therefore, COVID-19. Create a legacy of innovation that moves forward. ”
Holly M. McCabe et al, What Matters to Us: Impact of Telemedicine during the Pandemic in the Care of Sarcoma with Scotland, JCO Global…